All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Graft-versus-host disease (GvHD) is a systemic condition that occurs when immunocompetent T cells in the transplanted tissue (graft) attack the immunodeficient tissue of the recipient (host). GvHD is a common complication in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).1 Depending on the timing of the post-transplant occurrence of histocompatibility differences, GvHD is classified as1:
GvHD most commonly occurs following allo-HSCT. It can also manifest following the transfusion of un-irradiated blood and transplantation of solid organs (e.g., liver). Risk factors that increase the incidence of GvHD include unmatched donor transplants, human leukocyte antigen disparity, sex-mismatch between donor and recipient, and chemotherapy and radiation therapy causing total body irradiation. Cryopreservation of marrow, use of immunomodulators, and umbilical cord blood lower the incidence of GvHD.
The occurrence of aGvHD in patients undergoing allo-HSCT from an human leukocyte antigen (HLA)-matched sibling ranges between 9% and 50%, with a higher occurrence in unmatched donors.2 Chronic GvHD occurs in 6–80% of patients and is one of the main causes of mortality following allo-HSCT (Figure 1).1, 3-9
Figure 1. Epidemiology of GvHD*
aGvHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplant; cGvHD, chronic GvHD; US, United States.
*Adapted from Bachier, et al.3 ; Arai, et al.4 ; Akahoshi, et al.5; Bhatt, et al.6, Kumar, et al.7; Holtan, et al.8; DeFilipp, et al.9
The pathophysiology of GvHD is divided into three phases (Figure 2):
Figure 2. Pathophysiology of GvHD*
APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; GvHD, graft-versus-host disease; IDO, indoleamine 2, 3-dioxygenase; IFNγ, interferon gamma; LPS, lipopolysaccharide; TNFα, tumor necrosis factor alpha; Treg, regulatory T cell.
*Adapted from Ghimire, et al.10 Created with BioRender.com
In aGvHD, signs and symptoms most commonly occur around the time of donor engraftment. The most common organs affected in aGvHD include the skin, gastrointestinal tract, and liver.2 In cGvHD, symptoms typically occur within the first year after HSCT, but can occur as late as 7 years post-HSCT. Figure 3 shows the symptoms of both aGvHD and cGvHD. Symptoms can be used to differentiate between cGvHD and aGvHD, although "overlap syndrome" can occur, where typical aGvHD symptoms are present in a patient diagnosed with cGvHD.11
Figure 3. Signs and symptoms of A aGvHD and B cGvHD*
aGvHD, acute graft-versus-host disease; cGvHD, chronic GvHD.
*Adapted from Flowers and Martin.11; Jacobsohn and Vogelsang.12 Created with BioRender.com.
Symptoms of aGvHD are used to make a diagnosis, and biopsy can be performed to confirm it.12 Liver biopsy in patients with GvHD may reveal irregular bile ducts or early cytotoxic lymphocyte attack on the bile ducts. Endoscopy often reveals edema, sloughing of the mucosa, and sometimes bleeding. Findings present in skin biopsies can vary, and can include dyskeratotic keratinocytes, basal cell necrosis, and depletion of Langerhans cells.12
Early recognition of cGvHD manifestation and timely assessment of the affected organs is necessary for the diagnosis and management of cGvHD. The most used tests to diagnose GvHD include biopsy, radiography, and other testing to exclude other diagnoses.11
GvHD grading is important for assessing patients’ response to prophylactic treatments, the impact on survival, and association with graft-versus-leukemia effect. There are several grading systems developed for aGvHD; the most commonly used is the International Bone Marrow Transplant Registry grading system, defining the severity of aGvHD as13:
cGvHD grading is based on the National Institute for Health criteria as14:
Guidance on diagnosis may vary between countries, please check the key guidelines section below.
Prophylactic treatment in patients undergoing allo-HSCT is important for prevention of GvHD. The most commonly used prophylactic treatment is a combination of cyclosporine and methotrexate. In addition, antibacterial, antiviral, and antifungal prophylaxis are used to mitigate the risk of infections.1 Corticosteroids are the most commonly used treatment for GvHD, with the main focus of treatments being immunosuppression of donor T cells. Prednisone at a dose of 1 mg/kg should be used as a first-line treatment of newly diagnosed cGvHD.11
Treatments should focus on reducing the symptoms of GvHD while avoiding reducing the beneficial graft vs tumor response. The choice of treatment is based on the severity of symptoms and organ involvement. Figure 4 shows the criteria for treatment selection with corticosteroids.1
Figure 4. Treatment for GvHD*
GvHD, graft-versus-host disease.
*Adapted from Justiz Vaillant, et al.1
To prevent GvHD flares, gradual tapering of steroids is recommended. In patients receiving steroids for a longer period of time, octreotide can be given to reduce diarrhea. In addition, cyclosporine can be added to cGvHD treatment regimens to reduce steroid dosage.1
The GvHD Hub has reported on developments in the management of cGvHD. Currently, there are no standard second-line therapies for GvHD, and institutional advice should be followed depending on the location of the center; second-line therapies available for cGvHD are outlined in Figure 5.
Figure 5. Potential second-line therapies for cGvHD*
cGvHD, chronic graft-versus-host disease; JAK, Janus kinase.
*Data from GvHDHub.com.15
Guidance on management may vary between countries. Please see the section below on key guidelines for further information.
Justiz Vaillant AA, Modi P, Mohammadi O. Graft-versus-host Disease. In: StatPearls. StatPearls Publishing; 2024. http://www.ncbi.nlm.nih.gov/books/NBK538235/. Accessed August 15, 2024
Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-274. DOI: 1016/j.bbmt.2014.10.021
Bhatt VR, Wang T, Chen K, et al. Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: A Center for International Blood and Marrow Transplant Research analysis. Transplant Cell Ther. 2022;28(1):34-42. DOI: 1016/j.jtct.2021.10.002
DeFilipp Z, Alousi AM, Pidala JA, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5(20):4278-4284. doi:10.1182/bloodadvances.2021004941
Ghimire S, Weber D, Mavin E, et al. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol. 2017;8:79. DOI: 10.3389/fimmu.2017.00079
Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855-864. DOI: 1046/j.1365-2141.1997.1112925.x